nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—TNFSF11—leg—chronic obstructive pulmonary disease	0.0881	0.314	CbGeAlD
Lenalidomide—TNFSF11—respiratory system—chronic obstructive pulmonary disease	0.0219	0.0779	CbGeAlD
Lenalidomide—TNFSF11—connective tissue—chronic obstructive pulmonary disease	0.0193	0.0686	CbGeAlD
Lenalidomide—CDH5—respiratory system—chronic obstructive pulmonary disease	0.0165	0.0586	CbGeAlD
Lenalidomide—CDH5—connective tissue—chronic obstructive pulmonary disease	0.0145	0.0516	CbGeAlD
Lenalidomide—CDH5—bronchus—chronic obstructive pulmonary disease	0.0135	0.0482	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—chronic obstructive pulmonary disease	0.0133	0.0472	CbGeAlD
Lenalidomide—CDH5—trachea—chronic obstructive pulmonary disease	0.0122	0.0433	CbGeAlD
Lenalidomide—TNFSF11—lung—chronic obstructive pulmonary disease	0.0116	0.0414	CbGeAlD
Lenalidomide—PTGS2—leg—chronic obstructive pulmonary disease	0.0115	0.0408	CbGeAlD
Lenalidomide—CRBN—respiratory system—chronic obstructive pulmonary disease	0.0105	0.0372	CbGeAlD
Lenalidomide—CDH5—lung—chronic obstructive pulmonary disease	0.00874	0.0311	CbGeAlD
Lenalidomide—CRBN—bronchus—chronic obstructive pulmonary disease	0.0086	0.0306	CbGeAlD
Lenalidomide—CRBN—trachea—chronic obstructive pulmonary disease	0.00773	0.0275	CbGeAlD
Lenalidomide—Pomalidomide—TNF—chronic obstructive pulmonary disease	0.00602	0.299	CrCbGaD
Lenalidomide—CRBN—lung—chronic obstructive pulmonary disease	0.00555	0.0198	CbGeAlD
Lenalidomide—Pomalidomide—CYP1A2—chronic obstructive pulmonary disease	0.00441	0.219	CrCbGaD
Lenalidomide—Thalidomide—TNF—chronic obstructive pulmonary disease	0.00388	0.193	CrCbGaD
Lenalidomide—Thalidomide—CYP1A1—chronic obstructive pulmonary disease	0.00295	0.147	CrCbGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—CRP—chronic obstructive pulmonary disease	0.00288	0.0755	CbGpPWpGaD
Lenalidomide—PTGS2—respiratory system—chronic obstructive pulmonary disease	0.00285	0.0101	CbGeAlD
Lenalidomide—Thalidomide—CYP1A2—chronic obstructive pulmonary disease	0.00284	0.141	CrCbGaD
Lenalidomide—PTGS2—connective tissue—chronic obstructive pulmonary disease	0.00251	0.00892	CbGeAlD
Lenalidomide—CDH5—VEGFR2 mediated vascular permeability—NOS3—chronic obstructive pulmonary disease	0.00242	0.0635	CbGpPWpGaD
Lenalidomide—PTGS2—bronchus—chronic obstructive pulmonary disease	0.00234	0.00834	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	0.00229	0.00816	CbGeAlD
Lenalidomide—PTGS2—trachea—chronic obstructive pulmonary disease	0.0021	0.00749	CbGeAlD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—SCGB1A1—chronic obstructive pulmonary disease	0.00208	0.0545	CbGpPWpGaD
Lenalidomide—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.00176	0.00627	CbGeAlD
Lenalidomide—PTGS2—lung—chronic obstructive pulmonary disease	0.00151	0.00538	CbGeAlD
Lenalidomide—TNFSF11—Differentiation Pathway—VEGFA—chronic obstructive pulmonary disease	0.0015	0.0392	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—TGFB1—chronic obstructive pulmonary disease	0.00137	0.036	CbGpPWpGaD
Lenalidomide—ABCB1—trachea—chronic obstructive pulmonary disease	0.0013	0.00463	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—chronic obstructive pulmonary disease	0.00119	0.0312	CbGpPWpGaD
Lenalidomide—TNFSF11—IL6-mediated signaling events—IL6—chronic obstructive pulmonary disease	0.00105	0.0276	CbGpPWpGaD
Lenalidomide—TNFSF11—Differentiation Pathway—IL6—chronic obstructive pulmonary disease	0.00103	0.0271	CbGpPWpGaD
Lenalidomide—ABCB1—lung—chronic obstructive pulmonary disease	0.000935	0.00333	CbGeAlD
Lenalidomide—PTGS2—C-MYB transcription factor network—ELANE—chronic obstructive pulmonary disease	0.000912	0.0239	CbGpPWpGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—chronic obstructive pulmonary disease	0.000858	0.0225	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—NOS3—chronic obstructive pulmonary disease	0.000828	0.0217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—NOS3—chronic obstructive pulmonary disease	0.000782	0.0205	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—HMOX1—chronic obstructive pulmonary disease	0.000776	0.0203	CbGpPWpGaD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—chronic obstructive pulmonary disease	0.000705	0.0185	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000641	0.0168	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CRP—chronic obstructive pulmonary disease	0.000608	0.0159	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—VEGFA—chronic obstructive pulmonary disease	0.000597	0.0156	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—VEGFA—chronic obstructive pulmonary disease	0.000563	0.0148	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000553	0.0145	CbGpPWpGaD
Lenalidomide—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—chronic obstructive pulmonary disease	0.000507	0.0133	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD3—chronic obstructive pulmonary disease	0.000505	0.0132	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP12—chronic obstructive pulmonary disease	0.000495	0.013	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1A2—chronic obstructive pulmonary disease	0.000465	0.0122	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000435	0.0114	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.00042	0.011	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—IL6—chronic obstructive pulmonary disease	0.000413	0.0108	CbGpPWpGaD
Lenalidomide—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000405	0.000613	CcSEcCtD
Lenalidomide—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000405	0.000613	CcSEcCtD
Lenalidomide—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000405	0.000612	CcSEcCtD
Lenalidomide—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000402	0.000608	CcSEcCtD
Lenalidomide—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000399	0.000604	CcSEcCtD
Lenalidomide—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000396	0.0006	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—chronic obstructive pulmonary disease	0.000395	0.0104	CbGpPWpGaD
Lenalidomide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000395	0.000598	CcSEcCtD
Lenalidomide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000395	0.000598	CcSEcCtD
Lenalidomide—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000395	0.000597	CcSEcCtD
Lenalidomide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000393	0.000594	CcSEcCtD
Lenalidomide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000393	0.000594	CcSEcCtD
Lenalidomide—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000392	0.000593	CcSEcCtD
Lenalidomide—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.000592	CcSEcCtD
Lenalidomide—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000391	0.000592	CcSEcCtD
Lenalidomide—CDH5—Signaling by VEGF—IL6—chronic obstructive pulmonary disease	0.00039	0.0102	CbGpPWpGaD
Lenalidomide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000389	0.000589	CcSEcCtD
Lenalidomide—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000389	0.000589	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000388	0.0102	CbGpPWpGaD
Lenalidomide—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000388	0.000587	CcSEcCtD
Lenalidomide—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000386	0.000584	CcSEcCtD
Lenalidomide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.000584	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000385	0.000583	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.000583	CcSEcCtD
Lenalidomide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000382	0.000578	CcSEcCtD
Lenalidomide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000382	0.000578	CcSEcCtD
Lenalidomide—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00038	0.000576	CcSEcCtD
Lenalidomide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00038	0.000575	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000377	0.000571	CcSEcCtD
Lenalidomide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000377	0.00057	CcSEcCtD
Lenalidomide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000377	0.00057	CcSEcCtD
Lenalidomide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000376	0.000569	CcSEcCtD
Lenalidomide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000376	0.000569	CcSEcCtD
Lenalidomide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000374	0.000567	CcSEcCtD
Lenalidomide—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	0.000373	0.000565	CcSEcCtD
Lenalidomide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000373	0.000564	CcSEcCtD
Lenalidomide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.000563	CcSEcCtD
Lenalidomide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000372	0.000563	CcSEcCtD
Lenalidomide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000372	0.000562	CcSEcCtD
Lenalidomide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000371	0.000561	CcSEcCtD
Lenalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	0.000368	0.00965	CbGpPWpGaD
Lenalidomide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000368	0.000557	CcSEcCtD
Lenalidomide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000367	0.000556	CcSEcCtD
Lenalidomide—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000366	0.000554	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000365	0.000552	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000365	0.000552	CcSEcCtD
Lenalidomide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000364	0.000551	CcSEcCtD
Lenalidomide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000364	0.000551	CcSEcCtD
Lenalidomide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000364	0.000551	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00055	CcSEcCtD
Lenalidomide—Pain—Formoterol—chronic obstructive pulmonary disease	0.000361	0.000547	CcSEcCtD
Lenalidomide—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.000547	CcSEcCtD
Lenalidomide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000361	0.000547	CcSEcCtD
Lenalidomide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.000547	CcSEcCtD
Lenalidomide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.000546	CcSEcCtD
Lenalidomide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000358	0.000542	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000357	0.000541	CcSEcCtD
Lenalidomide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000357	0.00054	CcSEcCtD
Lenalidomide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.000538	CcSEcCtD
Lenalidomide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000355	0.000537	CcSEcCtD
Lenalidomide—Pain—Montelukast—chronic obstructive pulmonary disease	0.000354	0.000536	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000354	0.000535	CcSEcCtD
Lenalidomide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000353	0.000534	CcSEcCtD
Lenalidomide—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000352	0.000532	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000352	0.000532	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—MPO—chronic obstructive pulmonary disease	0.000352	0.00922	CbGpPWpGaD
Lenalidomide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.000532	CcSEcCtD
Lenalidomide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00035	0.00053	CcSEcCtD
Lenalidomide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00035	0.000529	CcSEcCtD
Lenalidomide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000349	0.000528	CcSEcCtD
Lenalidomide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000348	0.000527	CcSEcCtD
Lenalidomide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000348	0.000527	CcSEcCtD
Lenalidomide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000348	0.000526	CcSEcCtD
Lenalidomide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000347	0.000525	CcSEcCtD
Lenalidomide—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000347	0.000525	CcSEcCtD
Lenalidomide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000346	0.000524	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000346	0.000523	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000346	0.000523	CcSEcCtD
Lenalidomide—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000345	0.000523	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.000521	CcSEcCtD
Lenalidomide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000344	0.000521	CcSEcCtD
Lenalidomide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.000516	CcSEcCtD
Lenalidomide—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.000516	CcSEcCtD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—chronic obstructive pulmonary disease	0.00034	0.00891	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MPO—chronic obstructive pulmonary disease	0.000339	0.00889	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000339	0.000512	CcSEcCtD
Lenalidomide—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000338	0.000512	CcSEcCtD
Lenalidomide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000338	0.000512	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000338	0.00885	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000337	0.00883	CbGpPWpGaD
Lenalidomide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000336	0.000508	CcSEcCtD
Lenalidomide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000336	0.000508	CcSEcCtD
Lenalidomide—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.000506	CcSEcCtD
Lenalidomide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000334	0.000506	CcSEcCtD
Lenalidomide—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000334	0.000506	CcSEcCtD
Lenalidomide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.000506	CcSEcCtD
Lenalidomide—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.000333	0.000504	CcSEcCtD
Lenalidomide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000333	0.000504	CcSEcCtD
Lenalidomide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00033	0.0005	CcSEcCtD
Lenalidomide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00033	0.000499	CcSEcCtD
Lenalidomide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00033	0.000499	CcSEcCtD
Lenalidomide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000329	0.000498	CcSEcCtD
Lenalidomide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.000498	CcSEcCtD
Lenalidomide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000328	0.000496	CcSEcCtD
Lenalidomide—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000328	0.000496	CcSEcCtD
Lenalidomide—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000327	0.000495	CcSEcCtD
Lenalidomide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000327	0.000495	CcSEcCtD
Lenalidomide—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000327	0.000494	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.000494	CcSEcCtD
Lenalidomide—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000324	0.00049	CcSEcCtD
Lenalidomide—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000322	0.000487	CcSEcCtD
Lenalidomide—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000322	0.000487	CcSEcCtD
Lenalidomide—PTGS2—S1P1 pathway—VEGFA—chronic obstructive pulmonary disease	0.000321	0.00841	CbGpPWpGaD
Lenalidomide—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.000321	0.000485	CcSEcCtD
Lenalidomide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000317	0.00048	CcSEcCtD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000316	0.00828	CbGpPWpGaD
Lenalidomide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.000477	CcSEcCtD
Lenalidomide—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.000477	CcSEcCtD
Lenalidomide—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.000471	CcSEcCtD
Lenalidomide—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000311	0.000471	CcSEcCtD
Lenalidomide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000311	0.000471	CcSEcCtD
Lenalidomide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00031	0.00047	CcSEcCtD
Lenalidomide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.00031	0.000469	CcSEcCtD
Lenalidomide—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000308	0.000466	CcSEcCtD
Lenalidomide—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000305	0.000461	CcSEcCtD
Lenalidomide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000303	0.000459	CcSEcCtD
Lenalidomide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000303	0.000459	CcSEcCtD
Lenalidomide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000299	0.000452	CcSEcCtD
Lenalidomide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.000452	CcSEcCtD
Lenalidomide—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000298	0.000452	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000298	0.000452	CcSEcCtD
Lenalidomide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000297	0.000449	CcSEcCtD
Lenalidomide—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000294	0.000446	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000294	0.00772	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.000445	CcSEcCtD
Lenalidomide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000293	0.000443	CcSEcCtD
Lenalidomide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000289	0.000438	CcSEcCtD
Lenalidomide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.000438	CcSEcCtD
Lenalidomide—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000288	0.000435	CcSEcCtD
Lenalidomide—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.000287	0.000434	CcSEcCtD
Lenalidomide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000286	0.000433	CcSEcCtD
Lenalidomide—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000285	0.000431	CcSEcCtD
Lenalidomide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000283	0.000429	CcSEcCtD
Lenalidomide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.000427	CcSEcCtD
Lenalidomide—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00028	0.000424	CcSEcCtD
Lenalidomide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000279	0.000423	CcSEcCtD
Lenalidomide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.000423	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—chronic obstructive pulmonary disease	0.000275	0.00721	CbGpPWpGaD
Lenalidomide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000274	0.000414	CcSEcCtD
Lenalidomide—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000273	0.000414	CcSEcCtD
Lenalidomide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.000413	CcSEcCtD
Lenalidomide—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000269	0.000408	CcSEcCtD
Lenalidomide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000269	0.000407	CcSEcCtD
Lenalidomide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.000407	CcSEcCtD
Lenalidomide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.000403	CcSEcCtD
Lenalidomide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000266	0.000403	CcSEcCtD
Lenalidomide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000266	0.000403	CcSEcCtD
Lenalidomide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000266	0.000403	CcSEcCtD
Lenalidomide—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000266	0.000403	CcSEcCtD
Lenalidomide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000265	0.000401	CcSEcCtD
Lenalidomide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.000401	CcSEcCtD
Lenalidomide—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000265	0.0004	CcSEcCtD
Lenalidomide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000264	0.0004	CcSEcCtD
Lenalidomide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.000399	CcSEcCtD
Lenalidomide—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000264	0.000399	CcSEcCtD
Lenalidomide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000263	0.000398	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL13—chronic obstructive pulmonary disease	0.000262	0.00687	CbGpPWpGaD
Lenalidomide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000261	0.000395	CcSEcCtD
Lenalidomide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000261	0.000395	CcSEcCtD
Lenalidomide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.00026	0.000394	CcSEcCtD
Lenalidomide—Depression—Prednisone—chronic obstructive pulmonary disease	0.00026	0.000393	CcSEcCtD
Lenalidomide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000259	0.000392	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000257	0.000389	CcSEcCtD
Lenalidomide—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000256	0.000388	CcSEcCtD
Lenalidomide—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000256	0.000387	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000256	0.000387	CcSEcCtD
Lenalidomide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.000384	CcSEcCtD
Lenalidomide—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000253	0.000383	CcSEcCtD
Lenalidomide—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000252	0.000381	CcSEcCtD
Lenalidomide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.000381	CcSEcCtD
Lenalidomide—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000252	0.000381	CcSEcCtD
Lenalidomide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00038	CcSEcCtD
Lenalidomide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000251	0.00038	CcSEcCtD
Lenalidomide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000251	0.00038	CcSEcCtD
Lenalidomide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.000378	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.000373	CcSEcCtD
Lenalidomide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000246	0.000372	CcSEcCtD
Lenalidomide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000242	0.000366	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL17A—chronic obstructive pulmonary disease	0.000241	0.00632	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAPGEF3—chronic obstructive pulmonary disease	0.000239	0.00626	CbGpPWpGaD
Lenalidomide—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000238	0.000361	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000237	0.00622	CbGpPWpGaD
Lenalidomide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000237	0.000359	CcSEcCtD
Lenalidomide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000236	0.000357	CcSEcCtD
Lenalidomide—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000235	0.000356	CcSEcCtD
Lenalidomide—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000234	0.000354	CcSEcCtD
Lenalidomide—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000233	0.000352	CcSEcCtD
Lenalidomide—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.00023	0.000348	CcSEcCtD
Lenalidomide—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000229	0.000346	CcSEcCtD
Lenalidomide—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000225	0.000341	CcSEcCtD
Lenalidomide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000223	0.000338	CcSEcCtD
Lenalidomide—PTGS2—Overview of nanoparticle effects—IL6—chronic obstructive pulmonary disease	0.000222	0.00582	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000221	0.000335	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—GSTM1—chronic obstructive pulmonary disease	0.00022	0.00577	CbGpPWpGaD
Lenalidomide—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000219	0.000331	CcSEcCtD
Lenalidomide—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000329	CcSEcCtD
Lenalidomide—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000212	0.000321	CcSEcCtD
Lenalidomide—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000211	0.00032	CcSEcCtD
Lenalidomide—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000209	0.000316	CcSEcCtD
Lenalidomide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000207	0.000313	CcSEcCtD
Lenalidomide—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000207	0.000313	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.000311	CcSEcCtD
Lenalidomide—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000205	0.00031	CcSEcCtD
Lenalidomide—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000204	0.000308	CcSEcCtD
Lenalidomide—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000204	0.000308	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—HMOX1—chronic obstructive pulmonary disease	0.000203	0.00532	CbGpPWpGaD
Lenalidomide—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.000296	CcSEcCtD
Lenalidomide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000192	0.000291	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EDN1—chronic obstructive pulmonary disease	0.000191	0.00502	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000286	CcSEcCtD
Lenalidomide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000189	0.000285	CcSEcCtD
Lenalidomide—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000188	0.000285	CcSEcCtD
Lenalidomide—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000283	CcSEcCtD
Lenalidomide—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000186	0.000282	CcSEcCtD
Lenalidomide—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000184	0.000278	CcSEcCtD
Lenalidomide—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000277	CcSEcCtD
Lenalidomide—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000183	0.000277	CcSEcCtD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—chronic obstructive pulmonary disease	0.000182	0.00478	CbGpPWpGaD
Lenalidomide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.000275	CcSEcCtD
Lenalidomide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000179	0.000271	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—CRP—chronic obstructive pulmonary disease	0.000178	0.00467	CbGpPWpGaD
Lenalidomide—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000176	0.000266	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000176	0.0046	CbGpPWpGaD
Lenalidomide—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000263	CcSEcCtD
Lenalidomide—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000263	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000173	0.00455	CbGpPWpGaD
Lenalidomide—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000262	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000261	CcSEcCtD
Lenalidomide—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000259	CcSEcCtD
Lenalidomide—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000169	0.000255	CcSEcCtD
Lenalidomide—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000252	CcSEcCtD
Lenalidomide—Infection—Prednisone—chronic obstructive pulmonary disease	0.000165	0.00025	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL10—chronic obstructive pulmonary disease	0.000164	0.0043	CbGpPWpGaD
Lenalidomide—Shock—Prednisone—chronic obstructive pulmonary disease	0.000164	0.000248	CcSEcCtD
Lenalidomide—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000247	CcSEcCtD
Lenalidomide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000246	CcSEcCtD
Lenalidomide—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000162	0.000244	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000161	0.00423	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000243	CcSEcCtD
Lenalidomide—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000159	0.00024	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	0.000158	0.00415	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000157	0.0041	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—chronic obstructive pulmonary disease	0.000156	0.00408	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000229	CcSEcCtD
Lenalidomide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.000229	CcSEcCtD
Lenalidomide—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000228	CcSEcCtD
Lenalidomide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000149	0.000226	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000149	0.0039	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—chronic obstructive pulmonary disease	0.000149	0.0039	CbGpPWpGaD
Lenalidomide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000146	0.000222	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—NOS2—chronic obstructive pulmonary disease	0.000145	0.0038	CbGpPWpGaD
Lenalidomide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000145	0.000219	CcSEcCtD
Lenalidomide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.000218	CcSEcCtD
Lenalidomide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000144	0.000218	CcSEcCtD
Lenalidomide—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000217	CcSEcCtD
Lenalidomide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000143	0.000217	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	0.000142	0.00373	CbGpPWpGaD
Lenalidomide—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000215	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	0.000138	0.00362	CbGpPWpGaD
Lenalidomide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000137	0.000207	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SERPINE1—chronic obstructive pulmonary disease	0.000137	0.00359	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	0.000137	0.00359	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—ALB—chronic obstructive pulmonary disease	0.000137	0.00358	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000206	CcSEcCtD
Lenalidomide—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000136	0.000206	CcSEcCtD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	0.000136	0.00355	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	0.000135	0.00354	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000133	0.00349	CbGpPWpGaD
Lenalidomide—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000132	0.0002	CcSEcCtD
Lenalidomide—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000199	CcSEcCtD
Lenalidomide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000131	0.000199	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	0.000129	0.00337	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—chronic obstructive pulmonary disease	0.000127	0.00333	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000185	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—SERPINE1—chronic obstructive pulmonary disease	0.000122	0.0032	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000121	0.00317	CbGpPWpGaD
Lenalidomide—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000181	CcSEcCtD
Lenalidomide—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000178	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000116	0.00305	CbGpPWpGaD
Lenalidomide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000114	0.000172	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	0.000111	0.00292	CbGpPWpGaD
Lenalidomide—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000166	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000108	0.00284	CbGpPWpGaD
Lenalidomide—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000106	0.00016	CcSEcCtD
Lenalidomide—Rash—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000159	CcSEcCtD
Lenalidomide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000159	CcSEcCtD
Lenalidomide—Headache—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000158	CcSEcCtD
Lenalidomide—Nausea—Prednisone—chronic obstructive pulmonary disease	9.88e-05	0.000149	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—APIP—chronic obstructive pulmonary disease	9.46e-05	0.00248	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	9.17e-05	0.0024	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	8.96e-05	0.00235	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	8.79e-05	0.00231	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	8.59e-05	0.00225	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.49e-05	0.00223	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	8.4e-05	0.0022	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	8.29e-05	0.00217	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.1e-05	0.00212	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	8.07e-05	0.00212	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	7.28e-05	0.00191	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.19e-05	0.00188	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	6.83e-05	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	6.74e-05	0.00177	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	6.71e-05	0.00176	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	6.7e-05	0.00176	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	6.68e-05	0.00175	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	6.51e-05	0.00171	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.5e-05	0.0017	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	6.38e-05	0.00167	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.27e-05	0.00164	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	6.24e-05	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	6.21e-05	0.00163	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	6.1e-05	0.0016	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.84e-05	0.00153	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.67e-05	0.00149	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	5.63e-05	0.00147	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.36e-05	0.0014	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.25e-05	0.00138	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	5.15e-05	0.00135	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	5.06e-05	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	4.65e-05	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	4.56e-05	0.0012	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	4.51e-05	0.00118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.44e-05	0.00116	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.41e-05	0.00116	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	4.34e-05	0.00114	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	4.32e-05	0.00113	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.04e-05	0.00106	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.02e-05	0.00105	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	3.83e-05	0.001	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	3.59e-05	0.000941	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.45e-05	0.000903	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	3.34e-05	0.000876	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.33e-05	0.000873	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	3.3e-05	0.000864	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	3.29e-05	0.000863	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	3.23e-05	0.000847	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KL—chronic obstructive pulmonary disease	3.11e-05	0.000815	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	3.08e-05	0.000807	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.07e-05	0.000805	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	3e-05	0.000787	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.77e-05	0.000726	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	2.71e-05	0.000711	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.36e-05	0.000619	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.33e-05	0.000612	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	2.33e-05	0.000611	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.31e-05	0.000605	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.28e-05	0.000597	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.13e-05	0.000558	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.12e-05	0.000556	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.07e-05	0.000542	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.01e-05	0.000527	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.96e-05	0.000514	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	1.94e-05	0.000509	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.64e-05	0.000429	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	1.64e-05	0.000429	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.61e-05	0.000423	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	1.56e-05	0.000409	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.5e-05	0.000394	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.43e-05	0.000374	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	1.37e-05	0.000358	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.31e-05	0.000343	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	1.03e-05	0.000271	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	1.01e-05	0.000265	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	9.69e-06	0.000254	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	9.27e-06	0.000243	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	7.78e-06	0.000204	CbGpPWpGaD
